AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca imjudo (tremelimumab) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables
Latest, Q2 2026
83
Period ended Jun 30, 2026
Change on a year earlier
-6.7%
89 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
10
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Imjudo (tremelimumab) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 83 | -6.7% | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 77 | -3.7% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 93 | +27.4% | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 84 | +16.7% | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 89 | +20.3% | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 80 | +29.0% | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 73 | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 72 | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 74 | – | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 62 | – | Form 6-K FY2024Q1 Earnings Release ↗ |
Breakdown
What makes up imjudo (tremelimumab) — worldwide product sales ($m)
- Imjudo (tremelimumab) — Worldwide YoY actual (%)-7.0% · Q2 2026
- Imjudo (tremelimumab) — Worldwide YoY CER (%)-7.0% · Q2 2026
- Imjudo (tremelimumab) — US product sales ($M)51 · Q2 2026
- Imjudo (tremelimumab) — Emerging Markets product sales ($M)7 · Q2 2026
- Imjudo (tremelimumab) — Europe product sales ($M)14 · Q2 2026
- Imjudo (tremelimumab) — Established RoW product sales ($M)11 · Q2 2026
Cite this data
StockData. (2026). AstraZeneca Imjudo (tremelimumab) — Worldwide product sales ($M) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_imjudo_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.